Status:
COMPLETED
Procalcitonin in Hepatocellular Carcinoma
Lead Sponsor:
Ain Shams University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-70 years
Brief Summary
the value of serum procalcitonin in differentiation between bacterial infection and non infectious inflammation in febrile HCC patients following locoeregional treatment for HCC.
Eligibility Criteria
Inclusion
- \- Hepatocellular carcinoma patients who will undergo TACE and/or radio-frequency.
- \- Fever more than 38C after 48 hours post intervention.
Exclusion
- HCC Patients who does not develop fever after intervention.
- Proven infection elsewhere (e.g. UTI, chest infection..)
Key Trial Info
Start Date :
April 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT01518829
Start Date
April 1 2012
End Date
January 1 2013
Last Update
October 1 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tropical medicine department and hepatocellular carcinoma clinic
Cairo, Egypt